Research Topics
| Alan PollackSummaryAffiliation: University of Miami Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02Alan Pollack
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
Clin Cancer Res 15:5478-84. 2009..Here, we attempt to verify our prior findings and test the hypothesis that the relationship of the length of AD to patient outcome is affected by PKA(RIalpha) overexpression...
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02Li Yan Khor
Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
J Clin Oncol 27:3177-84. 2009..CONCLUSION Combined MDM2 and Ki-67 expression levels were independently related to distant metastasis and mortality and, if validated, could be considered for risk stratification of patients with prostate cancer in clinical trials...
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti
Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
J Clin Oncol 25:3082-9. 2007..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapyMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 59:1383-91. 2004..Intensity-modulated radiation therapy may offer further reductions in the doses received by the PB and CB; however, at what cost to prostate coverage and normal tissue sparing will be the subject of a follow-up study...
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancerRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
Cancer 100:538-43. 2004..CONCLUSIONS: Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation...
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:1151-60. 2007..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancerNiraj Pahlajani
Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
Int J Radiat Oncol Biol Phys 82:1949-56. 2012..However, local failure is also a major problem. We sought to establish the importance of more aggressive local radiotherapy (RT) to ≥80 Gy...
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 104:299-304. 2005..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 63:1455-62. 2005..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
Hazards of dose escalation in prostate cancer radiotherapyDeborah Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 57:1260-8. 2003..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluationSteven J Feigenberg
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 8:2268. 2007..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
What dose of external-beam radiation is high enough for prostate cancer?Thomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:682-9. 2007..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancerDeborah A Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 70:67-74. 2008..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 67:1082-7. 2007..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvementRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:695-701. 2005..These data suggest that the primary tumor takes precedence over lymph node coverage or the use of STAD. Doses >70 Gy are of paramount importance in such intermediate- and high-risk patients...
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivoZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prostate 68:599-609. 2008..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:1003-10. 2005..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implantThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 71:338-45. 2008..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapySteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 62:397-405. 2005..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 69:79-87. 2007..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapyPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 110:68-80. 2007..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 13:3585-90. 2007..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancerNavesh K Sharma
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 80:437-44. 2011..The present study compared the genitourinary and gastrointestinal (GI) toxicity in men treated with 3D-CRT+AD vs. IMRT+AD...
Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 71:1309-15. 2008....
Radiation dose and late failures in prostate cancerPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 67:1074-81. 2007..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 70:1487-91. 2008..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trialAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 64:518-26. 2006..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapyAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:19-23. 2003..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 58:43-52. 2004....
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivationMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 61:1291-8. 2005..The American Society of Therapeutic Radiation Oncology definition for biochemical failure overestimates BF in 20-30% after RT+AD compared to 5% after RT alone...
Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographsLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:903-11. 2007....
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
Int J Radiat Oncol Biol Phys 59:380-5. 2004..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach...
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapyMary Feng
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 68:1417-23. 2007..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancerSteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Am J Clin Oncol 29:458-62. 2006..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivationZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prostate 60:187-96. 2004..Antisense MDM2 has broad potential as a therapeutic agent to sensitize prostate cancer cells to AD therapy by enhancing apoptotic cell death...
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and IIJeff M Michalski
Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 56:192-8. 2003..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?Andre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
J Clin Oncol 25:3603-8. 2007..The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer. Materials and..
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?Deborah A Kuban
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 79:1310-7. 2011..To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer...
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?Khanh H Nguyen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:377-83. 2003....
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy aloneEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Urol 169:2153-7; discussion 2157-9. 2003..Additional analysis with large numbers of patients from multiple institutions is necessary to determine the point...
Gains from real-time tracking of prostate motion during external beam radiation therapyJin sheng Li
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Int J Radiat Oncol Biol Phys 75:1613-20. 2009..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
Does age matter in the selection of treatment for men with early-stage prostate cancer?Andre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 106:2598-602. 2006....
The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomogramsRadka Stoyanova
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Cancer 119:1080-8. 2013..The authors designed a model to estimate the results of various doses of radiotherapy (RT) combined with various durations of ADT...
MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatmentZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Phys Med Biol 57:535-45. 2012....
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10Li-Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:25-30. 2006..The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer...
Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapyMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 70:59-66. 2008..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
Does treatment duration affect outcome after radiotherapy for prostate cancer?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 72:1402-7. 2008..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
Experience of ultrasound-based daily prostate localizationAnurag Chandra
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 56:436-47. 2003..Although the accuracy of the BAT was not addressed in this investigation, we found a significant percentage of large shifts being made from the initial alignment position...
Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 71:938-41. 2008..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
Role of radiotherapy in ductal (endometrioid) carcinoma of the prostateThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 109:2011-5. 2007..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trialAlan Pollack
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 54:677-85. 2002..These issues were investigated in a cohort of men with Stage T1-T3 prostate cancer who were randomized to receive between 70 Gy and 78 Gy and were prospectively biopsied at about 2 years after the completion of radiotherapy (RT)...
MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRTLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 60:636-47. 2004....
Target localization for post-prostatectomy patients using CT and ultrasound image guidanceKamen Paskalev
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 6:40-9. 2005..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610Li-Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 104:962-7. 2005..CONCLUSIONS: MDM2 expression quantified by image analysis was weakly associated with DM. The cohort examined was relatively small and with larger patient numbers, MDM2 overexpression may emerge as a more significant covariate...
Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivoThirupandiyur S Udayakumar
Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
Int J Radiat Oncol Biol Phys 79:549-58. 2011..Here, we demonstrate the radiosensitization efficacy of adenovirus (Ad)-E2F1 infection in growing (orthotopic) LNCaP and (subcutaneous) PC3 nude mice xenograft tumors...
Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and deathPino Alcantara
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer 109:41-7. 2007..0001).CONCLUSIONS.nPSA12 is a strong independent predictor of outcome after RT alone for prostate cancer and should be useful in identifying patients at high risk for progression to metastasis and death...
Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatmentAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Urol Clin North Am 30:337-49, x. 2003..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerMatthew C Abramowitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 112:55-60. 2008..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?Alan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Nat Clin Pract Oncol 2:12-3. 2005
The Gleason score shift: score four and seven years agoDerek B Chism
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 56:1241-7. 2003..The GS shift confounds retrospective series spanning the 1990s...
Positive prostate biopsy laterality and implications for stagingMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 62:298-303. 2003..04). CONCLUSIONS: Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used...
Influence of number of CAG repeats on local control in the RTOG 86-10 protocolMay Abdel-Wahab
Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
Am J Clin Oncol 29:14-20. 2006..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatmentMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 58:743-9. 2004..A Phase III randomized trial has been designed to test the clinical significance of the erectile tissue-sparing technique described here...
Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation studyDarren J Little
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Urology 62:707-13. 2003..Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased...
Prostate cancer radiotherapy dose response: an update of the fox chase experienceAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Urol 171:1132-6. 2004....
Parameters for treatment decisions for salvage radiation therapyShelly Bowers Hayes
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 23:8204-11. 2005..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
Antisense Bcl-2 sensitizes prostate cancer cells to radiationZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prostate 65:331-40. 2005..CONCLUSIONS: To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect...
Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancerAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:22-30; discussion 30-1. 2002..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findingsBenjamin Movsas
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:634-9. 2002..The P/M PO2 ratio was the strongest predictor for biochemical control on stepwise multivariate analysis. Longer follow up with more patients is planned to confirm this result...
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-xAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 97:1630-8. 2003..The current study examined the association between expression levels of Ki-67, bcl-2, bax, and bcl-x in pretreatment biopsy specimens and patient outcome after definitive radiotherapy alone...
Treatment of prostate cancer with regional lymph node (N1) metastasisAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Radiat Oncol 13:121-9. 2003..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combinationZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 58:336-43. 2004..CONCLUSION: AS sensitizes cells to AD, RT, and AD+RT and shows promise in the treatment of the full range of patients with prostate cancer. AS has the potential to sensitize the primary tumor to AD+RT and metastasis to AD...
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialAlan Pollack
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 53:1097-105. 2002..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
Radiation therapy dose escalation for prostate cancer: a rationale for IMRTAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
World J Urol 21:200-8. 2003..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancerEugene H Huang
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Radiat Oncol Biol Phys 54:1314-21. 2002..Therefore, dose escalation may be safely achieved by adherence to dose-volume histogram constraints during treatment planning and organ localization at the time of treatment to ensure consistent patient setup...
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostateRobert A Price
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:843-52. 2003..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
Postprostatectomy radiation therapy for prostate cancerMatthew C Abramowitz
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Semin Radiat Oncol 18:15-22. 2008..Because the morbidity of postoperative radiotherapy is relatively low, when pathologic high risk factors are present adjuvant radiotherapy should be considered. The role of androgen deprivation postprostatectomy is less well defined...
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancerAndre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:408-15. 2006....
Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancerAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 70:671-7. 2008
Predictive models in external beam radiotherapy for clinically localized prostate cancerMack Roach
Department of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA
Cancer 115:3112-20. 2009..Cancer 2009;115(13 suppl):3112-20. (c) 2009 American Cancer Society...
Research Grants
- Radiation, Hormones & Antisense Prostate Cancer TherapyAlan Pollack; Fiscal Year: 2007..abstract_text> ..
